

# Stephen Forman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3737827/publications.pdf>

Version: 2024-02-01

659  
papers

17,535  
citations

17405

63  
h-index

19690

117  
g-index

801  
all docs

801  
docs citations

801  
times ranked

18269  
citing authors

#	ARTICLE	IF	CITATIONS
1	Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. <i>Blood</i> , 2000, 96, 4075-4083.	0.6	1,442
2	Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 2561-2569.	13.9	1,326
3	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. <i>Blood</i> , 2011, 118, 1255-1263.	0.6	496
4	CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells. <i>Cancer Research</i> , 2006, 66, 10995-11004.	0.4	435
5	Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. <i>Journal of Medical Virology</i> , 1994, 43, 103-110.	2.5	329
6	T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. <i>Blood</i> , 2013, 122, 3138-3148.	0.6	322
7	Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. <i>Blood</i> , 2000, 95, 1588-1593.	0.6	270
8	Phase 1 studies of central memoryâ€‘derived CD19 CAR Tâ€‘cell therapy following autologous HSCT in patients with B-cell NHL. <i>Blood</i> , 2016, 127, 2980-2990.	0.6	264
9	Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	263
10	T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-Bâ€‘lineage leukemia effect. <i>Blood</i> , 2003, 101, 1637-1644.	0.6	245
11	IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. <i>Cancer Immunology Research</i> , 2019, 7, 759-772.	1.6	235
12	S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites. <i>Cancer Cell</i> , 2012, 21, 642-654.	7.7	229
13	Regional Delivery of Chimeric Antigen Receptorâ€‘Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. <i>Clinical Cancer Research</i> , 2018, 24, 95-105.	3.2	220
14	Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e404-e407.	1.7	212
15	Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane. <i>Journal of Immunology</i> , 2008, 180, 7028-7038.	0.4	211
16	Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. <i>Blood</i> , 2010, 116, 3129-3139.	0.6	210
17	The myth of the second remission of acute leukemia in the adult. <i>Blood</i> , 2013, 121, 1077-1082.	0.6	192
18	Targeted Total Marrow Irradiation Using Three-Dimensional Image-Guided Tomographic Intensity-Modulated Radiation Therapy: An Alternative to Standard Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 306-315.	2.0	190

#	ARTICLE	IF	CITATIONS
19	A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 438-453.	2.0	182
20	Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). <i>Blood</i> , 2011, 118, 1413-1420.	0.6	176
21	Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy. <i>Molecular Therapy</i> , 2015, 23, 757-768.	3.7	169
22	Targeting Alpha-Fetoprotein (AFP)â€“MHC Complex with CAR T-Cell Therapy for Liver Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 478-488.	3.2	158
23	CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1376-1384.	1.9	153
24	TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3771-3782.	3.2	152
25	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-31.	0.8	152
26	Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. <i>Blood</i> , 2011, 117, 1888-1898.	0.6	151
27	Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	150
28	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. <i>Blood Advances</i> , 2016, 1, 250-259.	2.5	142
29	Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	140
30	Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. <i>Blood</i> , 2004, 104, 1898-1906.	0.6	139
31	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptorâ€“Redirected T Cells Against Multiple Myeloma. <i>Clinical Cancer Research</i> , 2018, 24, 106-119.	3.2	136
32	Durable Clinical, Cytogenetic, and Molecular Remissions After Allogeneic Hematopoietic Cell Transplantation for Refractory Sezary Syndrome and Mycosis Fungoides. <i>Journal of Clinical Oncology</i> , 2005, 23, 6163-6171.	0.8	134
33	Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2136-2140.	2.0	131
34	Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 858-865.	2.0	126
35	Clioma IL13R $\pm$ 2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis. <i>PLoS ONE</i> , 2013, 8, e77769.	1.1	126
36	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. <i>Nature Medicine</i> , 2018, 24, 450-462.	15.2	123

#	ARTICLE	IF	CITATIONS
37	CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. <i>Immunity</i> , 2016, 44, 913-923.	6.6	120
38	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancer Cell</i> , 2016, 30, 764-778.	7.7	116
39	A Retrospective Study of Patients Treated with Imatinib Mesylate Prior to Allogeneic Hematopoietic Stem Cell Transplant.. <i>Blood</i> , 2004, 104, 2752-2752.	0.6	113
40	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. <i>OncImmunology</i> , 2018, 7, e1380764.	2.1	111
41	PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with <sup>89</sup> Zr-Oxine. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1531-1537.	2.8	111
42	Enhanced antilymphoma efficacy of CD19-redirceted influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. <i>Blood</i> , 2005, 105, 1622-1631.	0.6	109
43	Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. <i>Blood</i> , 2008, 112, 903-909.	0.6	101
44	Comparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin's Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1326-1334.	2.0	98
45	Evidence of Donor-Derived Hematologic Malignancies after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 511-517.	2.0	96
46	Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients. <i>JAMA Oncology</i> , 2016, 2, 1277.	3.4	93
47	Autologous bone marrow transplantation for non-Hodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease. <i>British Journal of Haematology</i> , 1998, 103, 651-652.	1.2	92
48	Myeloid cell-targeted miR-146a mimic inhibits NF- $\kappa$ B-driven inflammation and leukemia progression in vivo. <i>Blood</i> , 2020, 135, 167-180.	0.6	88
49	IFN $\gamma$ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. <i>Cancer Discovery</i> , 2021, 11, 2248-2265.	7.7	86
50	Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 618-624.	2.0	84
51	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1025-e1034.	2.5	83
52	Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2268.	2.2	80
53	Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. <i>Blood</i> , 2011, 117, 309-315.	0.6	79
54	CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. <i>Cancer Discovery</i> , 2021, 11, 1192-1211.	7.7	78

#	ARTICLE	IF	CITATIONS
55	Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. <i>Molecular Therapy</i> , 2018, 26, 280-288.	3.7	76
56	Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. <i>Blood</i> , 2016, 127, 2249-2260.	0.6	74
57	Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. <i>Blood</i> , 2016, 128, 1050-1058.	0.6	74
58	Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1407-1414.	2.0	73
59	Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. <i>Blood</i> , 2017, 5, 26.		72
60	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3328-3339.	0.8	72
61	Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3037-3048.	1.9	71
62	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
63	Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. <i>Blood</i> , 2016, 127, 1687-1700.	0.6	70
64	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. <i>Blood</i> , 2021, 137, 471-484.	0.6	70
65	Stabilization of the c-Myc Protein by CAMKII $\beta$ Promotes T Cell Lymphoma. <i>Cancer Cell</i> , 2017, 32, 115-128.e7.	7.7	68
66	Polypeptide-Specific Antibody Response to Human Cytomegalovirus After Infection in Bone Marrow Transplant Recipients. <i>Journal of Infectious Diseases</i> , 1986, 153, 780-787.	1.9	67
67	Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. <i>Lancet Haematology</i> , 2016, 3, e87-e98.	2.2	67
68	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	67
69	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, 357-362.	1.7	66
70	Smart CARs engineered for cancer immunotherapy. <i>Current Opinion in Oncology</i> , 2015, 27, 466-474.	1.1	63
71	Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 938.e1-938.e6.	0.6	63
72	Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E253-E255.	2.0	62

#	ARTICLE	IF	CITATIONS
73	Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 265-269.	2.0	62
74	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. <i>Blood Advances</i> , 2021, 5, 4059-4063.	2.5	62
75	TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting. <i>Cancer Research</i> , 2014, 74, 5218-5228.	0.4	60
76	High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2000, 89, 680-689.	2.0	58
77	Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , 2017, 8, 978.	5.8	58
78	3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells. <i>Cell Stem Cell</i> , 2022, 29, 515-527.e8.	5.2	57
79	Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1864-1868.	2.0	56
80	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	1.2	56
81	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. <i>Leukemia</i> , 2021, 35, 189-200.	3.3	56
82	Primary anaplastic large-cell lymphoma associated with breast implants. <i>Leukemia and Lymphoma</i> , 2011, 52, 1481-1487.	0.6	55
83	Acute Lymphoblastic Leukemia in the Older Adult. <i>Journal of Oncology Practice</i> , 2019, 15, 67-75.	2.5	55
84	Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. <i>Blood Advances</i> , 2018, 2, 1756-1764.	2.5	53
85	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. <i>Clinical Cancer Research</i> , 2015, 21, 2993-3002.	3.2	52
86	Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 318-328.	1.5	51
87	Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. <i>Molecular Therapy</i> , 2021, 29, 2335-2349.	3.7	51
88	The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. <i>Journal of Cellular Physiology</i> , 2019, 234, 14040-14049.	2.0	50
89	Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 46-54.	2.1	49
90	Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, e45-e48.	1.2	49

#	ARTICLE	IF	CITATIONS
91	T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2015, 22, 484-488.	1.2	48
92	Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 463-475.	0.8	48
93	Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. <i>Cell Stem Cell</i> , 2019, 25, 542-557.e9.	5.2	48
94	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 1034-1044.	3.2	48
95	Hemolytic anemia in wilson disease: Clinical findings and biochemical mechanisms. <i>American Journal of Hematology</i> , 1980, 9, 269-275.	2.0	47
96	Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1900-1903.	2.0	47
97	Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 691-696.	2.0	46
98	Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. <i>Blood</i> , 2022, 139, 3605-3616.	0.6	46
99	Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. , 1996, 78, 1899-1905.		44
100	Cellular immunotherapy and autologous transplantation for hematologic malignancy. <i>Immunological Reviews</i> , 1997, 157, 231-240.	2.8	44
101	Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 575-578.	2.0	44
102	Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to <i>de novo</i> acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. <i>Haematologica</i> , 2018, 103, 1662-1668.	1.7	41
103	Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1025-1033.	0.4	41
104	Iron chelators induce autophagic cell death in multiple myeloma cells. <i>Leukemia Research</i> , 2014, 38, 988-996.	0.4	40
105	RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017, 176, 759-769.	1.2	40
106	Manufacturing of Large Numbers of Patient-specific T Cells for Adoptive Immunotherapy. <i>Journal of Immunotherapy</i> , 2007, 30, 644-654.	1.2	39
107	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2018, 32, 1567-1574.	3.3	39
108	Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. <i>Leukemia and Lymphoma</i> , 2011, 52, 1463-1473.	0.6	37

#	ARTICLE	IF	CITATIONS
109	Noncutaneous peripheral T-cell lymphoma histologically resembling mycosis fungoides. <i>Cancer</i> , 1982, 49, 1839-1847.	2.0	36
110	Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2003, 21, 615-623.	0.8	36
111	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 268-276.	2.0	36
112	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 978-986.	1.3	36
113	High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. <i>Cancer</i> , 1994, 73, 125-134.	2.0	34
114	L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. <i>PLoS ONE</i> , 2016, 11, e0146885.	1.1	34
115	CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. <i>Cancer Research</i> , 2017, 77, 5118-5128.	0.4	34
116	How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. <i>Blood</i> , 2020, 135, 804-813.	0.6	34
117	Trisomy 11: an association with stem/progenitor cell immunophenotype. <i>British Journal of Haematology</i> , 1995, 90, 266-273.	1.2	32
118	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e322-e327.	2.0	32
119	Treatment of allosensitized patients receiving allogeneic transplantation. <i>Blood Advances</i> , 2021, 5, 4031-4043.	2.5	32
120	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 514-520.	2.0	31
121	PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 239-239.	0.6	31
122	Extramedullary Relapse Following Total Marrow and Lymphoid Irradiation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 75-81.	0.4	30
123	Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1326-1329.	2.0	30
124	Are Disagreements in Caregiver and Patient Assessment of Patient Health Associated with Increased Caregiver Burden in Caregivers of Older Adults with Cancer?. <i>Oncologist</i> , 2017, 22, 1383-1391.	1.9	29
125	Pharmacokinetics of high-dose etoposide. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 561-564.	2.3	28
126	Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid. <i>JAMA Oncology</i> , 2020, 6, 1947.	3.4	28

#	ARTICLE	IF	CITATIONS
127	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1193-1199.	2.0	28
128	Mathematical Modeling of Chimeric TCR Triggering Predicts the Magnitude of Target Lysis and Its Impairment by TCR Downmodulation. <i>Journal of Immunology</i> , 2010, 184, 4284-4294.	0.4	27
129	Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 700-705.	2.0	27
130	Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood. <i>JAMA Oncology</i> , 2018, 4, e182453.	3.4	27
131	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2160-2166.	2.0	27
132	Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. <i>Current Opinion in Oncology</i> , 2012, 24, 182-190.	1.1	26
133	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. <i>Haematologica</i> , 2017, 102, 2030-2038.	1.7	26
134	Physiologic Frailty Among Hematopoietic Cell Transplantation (HCT) Survivors Suggests Accelerated Aging and Is a Predictor for Premature Mortality: A Report from the Bone Marrow Transplant Survivor Study (BMTSS). <i>Blood</i> , 2015, 126, 739-739.	0.6	26
135	Novel Redirected CAR Cell Immunotherapies for Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 576-584.	3.2	26
136	Comparison of naive and central memory derived CD8 <sup>+</sup> effector cell engraftment fitness and function following adoptive transfer. <i>Onc Immunology</i> , 2016, 5, e1072671.	2.1	25
137	B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. <i>Molecular Therapy</i> , 2018, 26, 695-707.	3.7	25
138	State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid Leukemia. <i>Cancer Research</i> , 2020, 80, 3157-3169.	0.4	25
139	Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2005, 106, 1130-1130.	0.6	25
140	Graft Versus Host Disease Correlates with Increased Survival After Allogeneic Stem Cell Transplant for Mature T-Cell Lymphomas: Evidence of Graft Versus T-Cell Lymphoma Effect. <i>Blood</i> , 2009, 114, 3367-3367.	0.6	25
141	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. <i>Cancer Immunology Research</i> , 2021, 9, 75-88.	1.6	24
142	Integrin $\beta 6$ signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells. <i>Oncogene</i> , 2020, 39, 2156-2169.	2.6	23
143	Acalculous cholecystitis in bone marrow transplant patients. <i>Cancer</i> , 1993, 71, 354-358.	2.0	22
144	Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 59, 124-135.	0.4	22

#	ARTICLE	IF	CITATIONS
145	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2020, 61, 309-317.	0.6	22
146	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. <i>Leukemia</i> , 2019, 33, 266-270.	3.3	21
147	Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. <i>Cytotherapy</i> , 2017, 19, 861-866.	0.3	20
148	Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1153-1161.	3.0	20
149	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1861-1869.	2.0	19
150	Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2517-2521.	2.0	19
151	In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	19
152	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 962-972.	2.9	19
153	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1084-1090.	2.0	19
154	Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression.. <i>Blood</i> , 2006, 108, 2165-2165.	0.6	19
155	The Pathophysiology of Graft-Vs.-Host Disease. , 0, , 353-368.		18
156	Gastrointestinal and Hepatic Complications. , 0, , 1434-1455.		18
157	Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 759-759.	0.6	18
158	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
159	Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 19-20.	0.6	17
160	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 529-535.	2.0	17
161	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 700-707.	2.0	16
162	Regulation of miR-34b/c-targeted gene expression program by SUMOylation. <i>Nucleic Acids Research</i> , 2018, 46, 7108-7123.	6.5	16

#	ARTICLE	IF	CITATIONS
163	Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL. <i>Blood</i> , 2012, 120, 3699-3699.	0.6	16
164	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 111.e1-111.e8.	0.6	16
165	PD-L1 blockade restores CAR T cell activity through IFN- $\gamma$ -regulation of CD163+ M2 macrophages. , 2022, 10, e004400.		16
166	Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2072-2075.	2.0	15
167	How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation. <i>Blood</i> , 2017, 130, 1976-1984.	0.6	15
168	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1828-1835.	2.0	15
169	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2383-2387.	2.0	15
170	Adults with Philadelphia Chromosome-“Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e41-e45.	2.0	15
171	The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. <i>Leukemia and Lymphoma</i> , 2020, 61, 2020-2023.	0.6	15
172	Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 902-910.	0.8	15
173	CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1015-1024.	3.3	15
174	Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2697-2708.	0.6	15
175	Uses and Growth of Hematopoietic Cell Transplantation. , 0, , 15-21.		14
176	Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. <i>Cancer</i> , 2018, 124, 850-857.	2.0	14
177	Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2139-2145.	2.0	14
178	Abnormal growth factor modulation of $\alpha$ 21-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors. <i>British Journal of Haematology</i> , 2001, 115, 845-853.	1.2	13
179	Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort. <i>British Journal of Haematology</i> , 2016, 174, 480-483.	1.2	13
180	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 292-299.	2.0	13

#	ARTICLE	IF	CITATIONS
181	Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 877-883.	1.3	13
182	Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1669-1677.	0.6	13
183	Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. <i>Blood Advances</i> , 2022, 6, 1444-1453.	2.5	13
184	Effect of Growth Factor Stimulation on Imatinib-Mediated Proliferation Inhibition and Apoptosis of CML CD34+ Cells. <i>Blood</i> , 2004, 104, 2967-2967.	0.6	13
185	Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021, 138, 133-133.	0.6	13
186	Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation. <i>Supportive Care in Cancer</i> , 2015, 23, 3141-3147.	1.0	12
187	Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1212-1217.	2.0	12
188	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2018, 11, 87.	6.9	12
189	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e400-e405.	0.2	12
190	Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report. <i>Journal of Clinical Oncology</i> , 2020, 38, 2872-2882.	0.8	12
191	Clinical and Genetic Risk Prediction of Cognitive Impairment After Blood or Marrow Transplantation for Hematologic Malignancy. <i>Journal of Clinical Oncology</i> , 2020, 38, 1312-1321.	0.8	12
192	A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. <i>Blood</i> , 2020, 136, 19-21.	0.6	12
193	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. <i>Blood</i> , 2015, 126, 796-796.	0.6	12
194	What is the role of reduced-intensity transplantation in the treatment of older patients with AML?. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 406-413.	0.9	11
195	Philadelphia chromosome as a recurrent event among therapy-related acute leukemia. <i>American Journal of Hematology</i> , 2017, 92, E18-E19.	2.0	11
196	Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 473-475.	1.3	11
197	Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy. <i>Blood Advances</i> , 2020, 4, 4798-4801.	2.5	11
198	Adult Patients with ALL Treated with CD62L+ T Naïve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile. <i>Blood</i> , 2018, 132, 4016-4016.	0.6	11

#	ARTICLE	IF	CITATIONS
199	Costimulatory Molecule Profiles After Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM) Patients. <i>Blood</i> , 2011, 118, 5108-5108.	0.6	11
200	Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 1991-2003.	0.8	11
201	Depletion of Host CCR7+ Dendritic Cells Prevented Donor T Cell Tissue Tropism in Anti-CD3â€“Conditioned Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 920-928.	2.0	10
202	Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report. <i>Blood</i> , 2018, 131, 2720-2729.	0.6	10
203	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10
204	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<sc>HMAâ€“Ven</sc>) or liposomal daunorubicinâ€“cytarabine (<sc>CPX</sc>â€“351). <i>American Journal of Hematology</i> , 2021, 96, E196-E200.	2.0	10
205	Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HIGH52 risk model. <i>Blood Advances</i> , 2021, 5, 4102-4111.	2.5	10
206	Uses and Growth of Hematopoietic Cell Transplantation. , 0, , 9-15.		10
207	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. <i>Blood</i> , 2019, 134, 4075-4075.	0.6	10
208	Acute myeloid leukemia therapeutics. <i>Oncolmmunology</i> , 2013, 2, e27214.	2.1	9
209	Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 922-929.	2.0	9
210	Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2261-2266.	2.0	9
211	Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. <i>Leukemia Research</i> , 2019, 87, 106230.	0.4	9
212	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1934-1941.	0.6	9
213	Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch. <i>Transplantation</i> , 2020, 104, 1070-1080.	0.5	9
214	Growth and Development after Hematopoietic Cell Transplantation. , 0, , 1608-1619.		9
215	CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL. <i>Blood</i> , 2018, 132, 610-610.	0.6	9
216	Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. <i>Blood</i> , 2015, 126, 519-519.	0.6	9

#	ARTICLE	IF	CITATIONS
217	Health-Related Quality of Life (HRQL) in Adult Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004, 104, 2254-2254.	0.6	9
218	Large-scale manufacturing and characterization of CMV-CD19CAR T cells. , 2022, 10, e003461.		9
219	The History of Autologous Hematopoietic Cell Transplantation. , 0, , 8-14.		8
220	Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 519-522.	0.2	8
221	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2464-2470.	1.3	8
222	Chronic Graft-versus-Host Disease: Clinical Manifestations and Therapy. , 0, , 1304-1324.		8
223	Updated Results of High-Dose Yttrium 90 (90Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AH SCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2007, 110, 1891-1891.	0.6	8
224	Single-cell analysis by mass cytometry reveals CD19 CAR T cell spatiotemporal plasticity in patients. <i>Oncolmmunology</i> , 2022, 11, 2040772.	2.1	8
225	A History of Allogeneic Hematopoietic Cell Transplantation. , 0, , 1-7.		7
226	Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e183-e185.	2.0	7
227	Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study. <i>Cancer</i> , 2020, 126, 3322-3329.	2.0	7
228	Self-endorsed cognitive problems versus objectively assessed cognitive impairment in blood or bone marrow transplantation recipients: A longitudinal study. <i>Cancer</i> , 2020, 126, 2174-2182.	2.0	7
229	Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study. <i>Cancer</i> , 2021, 127, 794-800.	2.0	7
230	Oral Complications of Hematopoietic Cell Transplantation. , 0, , 1589-1607.		7
231	Pregnancy Outcomes after Hematopoietic Cell Transplantation (HCT): A Report from the BMT Survivor Study.. <i>Blood</i> , 2004, 104, 58-58.	0.6	7
232	A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.. <i>Blood</i> , 2006, 108, 3043-3043.	0.6	7
233	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2013, 122, 2682-2682.	0.6	7
234	Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020â€”Report from World Marrow Donor Association. <i>Bone Marrow Transplantation</i> , 2022, 57, 1021-1024.	1.3	7

#	ARTICLE	IF	CITATIONS
235	Loss of SIRT1 inhibits hematopoietic stem cell aging and age-dependent mixed phenotype acute leukemia. <i>Communications Biology</i> , 2022, 5, 396.	2.0	7
236	Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	7
237	Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. <i>Blood Advances</i> , 2022, 6, 4936-4948.	2.5	7
238	Bone marrow transplantation for hematologic malignancies. <i>Journal of Cellular Physiology</i> , 1982, 113, 99-102.	2.0	6
239	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 0, , .	3.3	6
240	Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study. <i>British Journal of Haematology</i> , 2019, 186, 367-370.	1.2	6
241	Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 287-292.	2.0	6
242	Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 409-418.	1.3	6
243	Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e667-e672.	0.2	6
244	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1697-1703.	2.0	6
245	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 255.e1-255.e9.	0.6	6
246	Targeted In Vivo Delivery of NF- $\kappa$ B Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy. <i>Molecular Therapy</i> , 2021, 29, 1214-1225.	3.7	6
247	Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. <i>International Journal of Hematology</i> , 2021, 114, 544-553.	0.7	6
248	Pharmacologic Prevention of Acute Graft-Versus-Host Disease. , 0, , 1257-1274.		6
249	Herpes Simplex Virus Infections. , 0, , 1382-1387.		6
250	Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas. <i>Blood</i> , 2019, 134, 4023-4023.	0.6	6
251	Expression of DLK/PREF1 Results in Inhibition of Human Myeloid Cell Differentiation and Proliferation through Distinct Molecular Mechanisms.. <i>Blood</i> , 2004, 104, 202-202.	0.6	6
252	Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 664-664.	0.6	6

#	ARTICLE	IF	CITATIONS
253	Inhibition of MDR1 Overcomes Brentuximab Vedotin Resistance in Hodgkin Lymphoma Cell Line Model and Is Synergistic with Brentuximab Vedotin in Mouse Xenograft Model. <i>Blood</i> , 2016, 128, 752-752.	0.6	6
254	Donor CD8+ T Cells Mediate GVL without GVHD in Recipients Conditioned with Anti-CD3 mAb.. <i>Blood</i> , 2006, 108, 192-192.	0.6	6
255	Donor derived leukemia in allogeneic transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2823-2830.	0.6	6
256	Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. <i>Blood</i> , 2021, 138, 2502-2502.	0.6	6
257	Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	6
258	Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 344-359.	1.8	6
259	Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1011-1031.	0.9	5
260	The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies. <i>Leukemia Research</i> , 2019, 84, 106196.	0.4	5
261	Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1662-1664.	1.3	5
262	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
263	Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 3532-3533.	0.6	5
264	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1425-1432.	2.0	5
265	Immunological Reconstitution Following Hematopoietic Cell Transplantation. , 0, , 853-861.		5
266	Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies. , 0, , 1043-1058.		5
267	Fungal Infections after Hematopoietic Cell Transplantation. , 0, , 1346-1366.		5
268	Cytomegalovirus Infection. , 0, , 1367-1381.		5
269	Varicella-zoster Virus Infections. , 0, , 1388-1409.		5
270	Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1636-1636.	0.6	5

#	ARTICLE	IF	CITATIONS
271	Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope.. Blood, 2004, 104, 894-894.	0.6	5
272	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. A California Cancer Consortium Study.. Blood, 2008, 112, 1564-1564.	0.6	5
273	Pre-Transplant R-Bendamustine Induces High Rates of Minimal Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma. Blood, 2015, 126, 518-518.	0.6	5
274	Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood, 2017, 130, 738-738.	0.6	5
275	Ethnic Differences in the Prevalence of, and Predictors for Anxiety, Depression, and Somatic Distress in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood, 2008, 112, 741-741.	0.6	5
276	Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. Biology of Blood and Marrow Transplantation, 2020, 26, 1386-1393.	2.0	5
277	Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade. Blood, 2021, 138, 234-234.	0.6	5
278	Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity. Blood Advances, 2022, 6, 1645-1650.	2.5	5
279	Microcytosis in Hodgkin disease associated with unbalanced globin chain synthesis. American Journal of Hematology, 1986, 23, 123-129.	2.0	4
280	Efficacy of blinatumomab for MRD relapse in ALL post allogeneic HCT. Leukemia Research, 2021, 104, 106579.	0.4	4
281	Hematopoietic Cell Donors. , 0, , 538-549.		4
282	Cytomegalovirus Infection. , 0, , 701-726.		4
283	Growth and Development After Hematopoietic Cell Transplantation. , 0, , 929-943.		4
284	Delayed Nonmalignant Complications after Hematopoietic Cell Transplantation. , 0, , 1620-1637.		4
285	Murine Models of Graft-versus-Host Disease and Graft-versus-Tumor Effect. , 0, , 176-187.		4
286	Pharmacologic Basis for High-dose Chemotherapy. , 0, , 287-315.		4
287	Bone Marrow and Peripheral Blood Cell Donors and Donor Registries. , 0, , 544-558.		4
288	Kidney and Bladder Complications of Hematopoietic Cell Transplantation. , 0, , 1473-1486.		4

#	ARTICLE	IF	CITATIONS
289	Haploidentical mixed chimerism cures autoimmunity in established type 1 diabetic mice. Journal of Clinical Investigation, 2020, 130, 6457-6476.	3.9	4
290	Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning. Blood, 2019, 134, 669-669.	0.6	4
291	Functional Limitations, Physical Disability and Social Competence among HCT Survivors Transplanted during Childhood or Adolescence: A Report from the Bone Marrow Transplant Survivor Study.. Blood, 2004, 104, 59-59.	0.6	4
292	Pre-Clinical Development of a Subunit Vaccine Expressing an IE1-IE2 Fusion Protein of HCMV.. Blood, 2007, 110, 165-165.	0.6	4
293	Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Complete Cytogenetic Remission on Imatinib Treatment for 5 Years. Blood, 2008, 112, 194-194.	0.6	4
294	First in Human Engraftment of Anti-HIV Lentiviral Vector Gene Modified CD34+ Peripheral Blood Progenitor Cells in the Treatment of AIDS Related Lymphoma (ARL).. Blood, 2008, 112, 2348-2348.	0.6	4
295	A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR.. Blood, 2009, 114, 2194-2194.	0.6	4
296	Neurocognitive Function and Its Impact On Return to Work in Patients Treated with Hematopoietic Cell Transplantation (HCT).. Blood, 2009, 114, 521-521.	0.6	4
297	Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333. Blood, 2014, 124, 2399-2399.	0.6	4
298	Treatment with Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 861-861.	0.6	4
299	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor Redirected-T Cells Against Multiple Myeloma. Blood, 2016, 128, 812-812.	0.6	4
300	Donor CD8+ T Cells Facilitate Induction of Chimerism and Tolerance without GVHD in Autoimmune NOD Mice Conditioned with Anti-CD3 mAb.. Blood, 2004, 104, 1204-1204.	0.6	4
301	Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL).. Blood, 2009, 114, 2323-2323.	0.6	4
302	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. American Journal of Hematology, 2022, 97, .	2.0	4
303	Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission. Transplantation and Cellular Therapy, 2022, 28, 368.e1-368.e7.	0.6	4
304	Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation. Transplantation and Cellular Therapy, 2022, 28, 367.e1-367.e9.	0.6	4
305	Biology of Hematopoietic Stem and Progenitor Cells. , 0, , 69-95.		3
306	Role of reduced intensity transplant in adult patients with acute lymphoblastic leukemia: If and when?. Best Practice and Research in Clinical Haematology, 2009, 22, 557-566.	0.7	3

#	ARTICLE	IF	CITATIONS
307	Identification of a CD133 <sup>+</sup> CD55 <sup>+</sup> population functions as a fetal common skeletal progenitor. <i>Scientific Reports</i> , 2016, 6, 38632.	1.6	3
308	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 486-493.	2.0	3
309	Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. <i>Cancer</i> , 2019, 125, 4033-4042.	2.0	3
310	Hematopoietic Cell Transplantation for Immunodeficiency Diseases. , 0, , 1430-1442.		3
311	T-Cell Depletion to Prevent Graft-vs.-Host Disease. , 0, , 221-233.		3
312	Mechanisms of Tolerance. , 0, , 300-323.		3
313	Gastrointestinal and Hepatic Complications. , 0, , 769-810.		3
314	Secondary Malignancies After Hematopoietic Cell Transplantation. , 0, , 962-977.		3
315	Nutrition Support of the Hematopoietic Cell Transplant Recipient. , 0, , 1551-1569.		3
316	Neurologic Complications of Hematopoietic Cell Transplantation. , 0, , 1653-1663.		3
317	High-dose Preparatory Regimens. , 0, , 316-332.		3
318	The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation. , 0, , 443-460.		3
319	Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy. , 0, , 590-604.		3
320	Hematopoietic Cell Transplantation from Unrelated Donors. , 0, , 675-691.		3
321	Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia. , 0, , 761-774.		3
322	Hematopoietic Cell Transplantation for Storage Diseases. , 0, , 1136-1162.		3
323	Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation. , 0, , 1226-1243.		3
324	Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults. <i>Blood</i> , 2018, 132, 1552-1552.	0.6	3

#	ARTICLE	IF	CITATIONS
325	Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT. <i>Blood</i> , 2013, 122, 3374-3374.	0.6	3
326	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 522-522.	0.6	3
327	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 679-679.	0.6	3
328	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	0.6	3
329	Hematopoietic Cell Transplantation for Storage Diseases. , 0, , 1455-1470.		3
330	Severe/Life-Threatening/Fatal Chronic Health Conditions (CHCs) after Allogeneic Blood or Marrow Transplantation (BMT) in Childhood - a Report from the BMT Survivor Study (BMTSS). <i>Blood</i> , 2020, 136, 12-13.	0.6	3
331	Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 41-42.	0.6	3
332	Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report. <i>Blood Advances</i> , 2022, 6, 2471-2479.	2.5	3
333	Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma. <i>Cancer</i> , 2022, 128, 1392-1401.	2.0	3
334	A History of Bone Marrow Transplantation. , 0, , 1-8.		3
335	Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia. , 0, , 979-1001.		3
336	Hematopoietic Cell Transplantation from HLA Partially Matched Related Donors. , 0, , 1116-1131.		3
337	Innovations in autologous transplantation for hematologic malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 28-33.	2.0	2
338	The Pathophysiology of Graft-Versus-Host Disease. , 0, , 208-221.		2
339	Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2. <i>Leukemia</i> , 2018, 32, 2706-2709.	3.3	2
340	Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 851-858.	1.1	2
341	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 125.	2.8	2
342	Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. <i>Frontiers in Immunology</i> , 2021, 12, 700045.	2.2	2

#	ARTICLE	IF	CITATIONS
343	Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. , 1996, 78, 1899.		2
344	Murine Models for Graft-Vs.-Host Disease. , 0, , 344-352.		2
345	Fungal Infections After Hematopoietic Cell Transplantation. , 0, , 683-700.		2
346	Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients. , 0, , 1664-1670.		2
347	Psychosocial Issues in Hematopoietic Cell Transplantation. , 0, , 488-501.		2
348	Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders. , 0, , 827-844.		2
349	Self-Endorsed Cognitive Problems Vs. Objectively-Assessed Cognitive Impairment in Blood or Marrow Transplantation (BMT) Recipients â€” a Longitudinal Study. Blood, 2018, 132, 619-619.	0.6	2
350	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma. Blood, 2018, 132, 2177-2177.	0.6	2
351	The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma. Blood, 2018, 132, 965-965.	0.6	2
352	Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). Blood, 2020, 136, 37-38.	0.6	2
353	Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial. Blood, 2020, 136, 49-50.	0.6	2
354	Primary Anaplastic Large Cell Lymphoma of the Breast Occurring in Patients with Silicone Breast Implants.. Blood, 2004, 104, 4563-4563.	0.6	2
355	Total Marrow Irradiation (TMI) with Helical Tomotherapy and PBPC Following High-Dose Melphalan and PBPC as Part of Tandem Therapy for Patients with Multiple Myeloma.. Blood, 2005, 106, 1176-1176.	0.6	2
356	Burdern of Long-Term Morbidity after Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor Study (BMTSS).. Blood, 2007, 110, 832-832.	0.6	2
357	HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for B Cell Non Hodgkin Lymphoma (NHL).. Blood, 2008, 112, 2181-2181.	0.6	2
358	Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.. Blood, 2009, 114, 2771-2771.	0.6	2
359	Matched Cohort Analysis of Allogeneic Hematopoietic Cell Transplantation (HCT) with Total Marrow Irradiation/Fludarabine/Melphalan (TFM) Versus Fludarabine/Melphalan (FM) Conditioning for Acute Leukemia. Blood, 2012, 120, 222-222.	0.6	2
360	Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells. Blood, 2015, 126, 51-51.	0.6	2

#	ARTICLE	IF	CITATIONS
361	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 930-930.	0.6	2
362	Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL). <i>Cancer Treatment and Research</i> , 2021, 181, 179-196.	0.2	2
363	The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 2866-2866.	0.6	2
364	A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.. <i>Blood</i> , 2006, 108, 1948-1948.	0.6	2
365	Late Hospitalizations in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): Report From the Bone Marrow Transplant Study (BMTSS).. <i>Blood</i> , 2009, 114, 807-807.	0.6	2
366	Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and PBPC as part of tandem autologous transplant (TAT) for patients with multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8581-8581.	0.8	2
367	Nursing Role in Hematopoietic Cell Transplantation. , 0, , 461-477.		2
368	Autologous Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma. , 0, , 1207-1220.		2
369	Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	2
370	Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. <i>Blood</i> , 2020, 136, 40-41.	0.6	2
371	Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. <i>Bone Marrow Transplantation</i> , 2022, 57, 830-833.	1.3	2
372	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1220-1226.	0.6	2
373	Graft-Vs.-Tumor Responses. , 0, , 369-379.		2
374	Clinical and Administrative Support for Hematopoietic Cell Transplant Programs. , 0, , 463-468.		2
375	Psychosocial Issues in Hematopoietic Cell Transplantation. , 0, , 497-506.		2
376	Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Support of High-Dose Cancer Therapy. , 0, , 576-587.		2
377	Allogeneic Hematopoietic Cell Transplantation for Adult Patients With Acute Myeloid Leukemia. , 0, , 1025-1039.		2
378	Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma. <i>Neoplasia</i> , 2022, 30, 100801.	2.3	2

#	ARTICLE	IF	CITATIONS
379	The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2754-2756.	0.6	2
380	Immune Reconstitution Following Hematopoietic Cell Transplantation. , 0, , 222-231.		1
381	Expansion of Hematopoietic Stem Cells. , 0, , 88-101.		1
382	Biology of Hematopoietic Stem and Progenitor Cells. , 0, , 36-63.		1
383	Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1264-1268.	2.0	1
384	Rebound thrombocytosis is associated with response in <scp>AML</scp> patients treated with venetoclax and hypomethylating agents. <i>American Journal of Hematology</i> , 2021, 96, E140-E143.	2.0	1
385	Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation Survivors. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2073-2076.e5.	0.3	1
386	Clinical Trials of Gene Marking and Gene Therapy Using Hematopoietic Stem Cells. , 0, , 118-129.		1
387	Preparative Regimens and Modification of Regimen-Related Toxicities. , 0, , 158-177.		1
388	Antibody Mediated Purging. , 0, , 244-253.		1
389	The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases. , 0, , 324-343.		1
390	Overview of Hematopoietic Cell Transplantation Immunology. , 0, , 16-30.		1
391	Herpes Simplex Virus Infections. , 0, , 727-731.		1
392	Epstein-Barr Virus Infection. , 0, , 749-756.		1
393	Allogeneic Transplantation for Myelodysplastic and Myeloproliferative Disorders. , 0, , 1084-1095.		1
394	Hematopoietic Cell Transplantation from Unrelated Donors. , 0, , 1132-1149.		1
395	Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 1262-1282.		1
396	Hematopoietic Cell Transplantation for Neuroblastoma. , 0, , 1333-1344.		1

#	ARTICLE	IF	CITATIONS
397	The Human Graft-versus-Tumor Response“ and How to Exploit It. , 0, , 232-247.		1
398	Dendritic Cells in Hematopoietic Cell Transplantation. , 0, , 248-263.		1
399	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation. , 0, , 365-375.		1
400	Pathology of Hematopoietic Cell Transplantation. , 0, , 390-405.		1
401	Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients. , 0, , 502-514.		1
402	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults. , 0, , 791-805.		1
403	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children. , 0, , 806-826.		1
404	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. , 0, , 897-913.		1
405	Hematopoietic Cell Transplantation for Immunodeficiency Diseases. , 0, , 1105-1124.		1
406	Vascular Access and Complications. , 0, , 1244-1256.		1
407	First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results. Blood, 2019, 134, 4394-4394.	0.6	1
408	Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. Blood, 2019, 134, 4518-4518.	0.6	1
409	Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. Blood, 2019, 134, 4525-4525.	0.6	1
410	Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy with Interleukin-2 Versus Observation for Patients with Non-Hodgkin’s Lymphoma: Results of a Phase III Randomized Trial by the Southwest Oncology Group (SWOG 9438).. Blood, 2006, 108, 326-326.	0.6	1
411	Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.. Blood, 2007, 110, 4989-4989.	0.6	1
412	Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM).. Blood, 2008, 112, 3326-3326.	0.6	1
413	Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor. Blood, 2008, 112, 797-797.	0.6	1
414	Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.. Blood, 2012, 120, 3151-3151.	0.6	1

#	ARTICLE	IF	CITATIONS
415	Genetic Susceptibility to Anthracycline-Related Congestive Heart Failure (CHF) in Survivors of Hematopoietic Cell Transplantation (HCT). Blood, 2012, 120, 589-589.	0.6	1
416	Selection For Brentuximab Vedotin Resistant Lymphoma Cell Lines Leads To Downregulation Of Surface CD30 Expression. Blood, 2013, 122, 1280-1280.	0.6	1
417	In Vivo Targeting Of Acute Myeloid Leukemia Using CpG-Stat3 siRNA Results In T Cell-Dependent Tumor Eradication. Blood, 2013, 122, 4212-4212.	0.6	1
418	Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma. Blood, 2013, 122, 4398-4398.	0.6	1
419	CS-1 Re-Directed Central Memory T Cell Therapy for Multiple Myeloma. Blood, 2014, 124, 1114-1114.	0.6	1
420	Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies. Blood, 2014, 124, 4483-4483.	0.6	1
421	Matched Unrelated Donor Hematopoietic Cell Transplantation Following Reduced-Intensity Conditioning for Treatment of Myelofibrosis.. Blood, 2004, 104, 2769-2769.	0.6	1
422	Feasibility and Efficacy of Mobilization of BCR/ABL- PBSC in CML Patients Receiving Imatinib.. Blood, 2004, 104, 2858-2858.	0.6	1
423	Delayed Cytomegalovirus (cmv) Infection Following Hematopoietic Cell Transplantation (HCT): City of Hope (COH) Experience.. Blood, 2008, 112, 1155-1155.	0.6	1
424	Purity, Potency and Safety: Quality Management Reports (QMR) as the Basis for An Effective Continuous Process Improvement System in An Academic Gene Therapy Program.. Blood, 2009, 114, 1417-1417.	0.6	1
425	A Phase I Trial of Total Marrow and Lymphoid Irradiation (TMLI)-Based Transplant Conditioning in Patients (Pts) with Relapsed/Refractory Acute Leukemia. Blood, 2015, 126, 735-735.	0.6	1
426	Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. Blood, 2018, 132, 3416-3416.	0.6	1
427	Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant) Tj ETQq1 1 0.784314.6gBT /Overlock 1	0.6	1
428	Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R. Blood, 2019, 134, 3871-3871.	0.6	1
429	Burden of Long-Term Morbidity Borne By Survivors of Acute Myeloid Leukemia (AML) Treated with Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). Blood, 2019, 134, 707-707.	0.6	1
430	Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS). Blood, 2019, 134, 699-699.	0.6	1
431	Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. Blood, 2019, 134, 5729-5729.	0.6	1
432	In Utero Transplantation. , 0, , 577-589.		1

#	ARTICLE	IF	CITATIONS
433	Histocompatibility. , 0, , 145-162.		1
434	Dexamethasone Enhanced CAR T Cell Persistence and Function through Upregulation of Interleukin 7 Receptor. Blood, 2021, 138, 1715-1715.	0.6	1
435	Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL). Blood, 2021, 138, 2836-2836.	0.6	1
436	Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity. Blood, 2021, 138, 2796-2796.	0.6	1
437	A Randomized Open Label Pilot Study of <i>Clostridium Butyricum</i> Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 334-334.	0.6	1
438	Social Vulnerability Is a Clinically Important Predictor of Outcomes after Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 842-842.	0.6	1
439	Outcomes Research in Hematopoietic Cell Transplantation. , 0, , 428-441.		1
440	Radiotherapeutic Principles of Hematopoietic Cell Transplantation. , 0, , 178-197.		1
441	Radioimmunotherapy and Hematopoietic Cell Transplantation. , 0, , 198-208.		1
442	Pharmacologic Purging of Bone Marrow. , 0, , 254-257.		1
443	Adoptive Immunotherapy With Antigen-Specific T Cells. , 0, , 380-404.		1
444	In Utero Transplantation. , 0, , 565-575.		1
445	Hematopoietic Cell Donor Registries. , 0, , 624-631.		1
446	Varicella-Zoster Virus Infections. , 0, , 732-748.		1
447	Pulmonary Complications After Hematopoietic Cell Transplantation. , 0, , 873-882.		1
448	Nutritional Support of Hematopoietic Cell Recipients. , 0, , 883-893.		1
449	Oral Complications. , 0, , 911-928.		1
450	Allogeneic Transplantation for Chronic Myeloid Leukemia. , 0, , 1007-1017.		1

#	ARTICLE	IF	CITATIONS
451	Allogeneic Transplantation for Acute Lymphoblastic Leukemia in Children. , 0, , 1067-1083.		1
452	Allogeneic Transplantation for Lymphoma and Chronic Lymphocytic Leukemia. , 0, , 1105-1115.		1
453	Allogeneic Hematopoietic Cell Transplantation for Solid Tumors. , 0, , 1177-1187.		1
454	Hematopoietic Cell Transplantation for Breast Cancer. , 0, , 1298-1307.		1
455	Hematopoietic Cell Transplantation for Pediatric Patients With Solid Tumors. , 0, , 1354-1368.		1
456	The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases. , 0, , 264-285.		1
457	Hematopoietic Cell Transplantation for Autoimmune Diseases. , 0, , 1014-1029.		1
458	Hematopoietic Cell Transplantation for Osteopetrosis. , 0, , 1125-1135.		1
459	Abstract CT541A: Oncolytic viral reshaping of the tumor microenvironment to promote CAR T cell therapy for glioblastoma. Cancer Research, 2022, 82, CT541A-CT541A.	0.4	1
460	Autologous Graft-vs.-Host Disease. , 0, , 405-413.		0
461	Should patients with acute lymphoblastic leukemia receive hematopoietic stem-cell transplant from an unrelated donor?. Nature Clinical Practice Oncology, 2005, 2, 18-19.	4.3	0
462	Radiotherapeutic Principles of Hematopoietic Cell Transplantation. , 0, , 333-350.		0
463	Molecular Biology of Stem Cell Renewal. , 0, , 64-71.		0
464	Mechanisms of Tolerance. , 0, , 188-207.		0
465	Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation. , 0, , 102-115.		0
466	Cellular Biology of Hematopoiesis. , 0, , 72-87.		0
467	Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 845-859.		0
468	Response: A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 different conditioning regimens. Blood, 2010, 115, 4317-4317.	0.6	0

#	ARTICLE	IF	CITATIONS
469	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 837.e1-837.e10.	0.6	0
470	Health Care Utilization by Hematopoietic Cell Transplantation (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004, 104, 2196-2196.	0.6	0
471	Cytomegalovirus Infections Following Reduced-Intensity Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 2245-2245.	0.6	0
472	Depression, Somatic Distress and Anxiety in Adult Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004, 104, 231-231.	0.6	0
473	Prognostic Relevance of "Early-Onset" Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.. <i>Blood</i> , 2004, 104, 423-423.	0.6	0
474	Predictors of Avascular Necrosis (AVN) of Bone after Long-Term Follow-Up of Allogeneic and Autologous Hematopoietic Cell Transplantation (HCT) for Malignant and Non-Malignant Disorders.. <i>Blood</i> , 2005, 106, 700-700.	0.6	0
475	Peptide Libraries to CMV Antigens Predict Levels of Cytotoxic Function of CMV-Specific CTL Populations in PBMC from HSCT Recipients.. <i>Blood</i> , 2005, 106, 478-478.	0.6	0
476	Large Granular Lymphocytosis Following Transplantation: Institutional Experience over a 10-Year Period at City of Hope.. <i>Blood</i> , 2005, 106, 2024-2024.	0.6	0
477	Pre-Stimulation of CML CD34+ Cells with High Concentrations of Growth Factors Counters Imatinib-Mediated Proliferation Suppression and Enhances Apoptosis of Non-Dividing Cells.. <i>Blood</i> , 2005, 106, 2479-2479.	0.6	0
478	Effects of Elevated BCR/ABL Expression Level on Cellular Transformation and Sensitivity to Imatinib in Primitive Human Hematopoietic Cells.. <i>Blood</i> , 2005, 106, 1998-1998.	0.6	0
479	Impact of Chronic Graft Versus Host Disease (cGVHD) on the Health Status of Hematopoietic Cell Transplantation (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2005, 106, 702-702.	0.6	0
480	The MDS-Associated Gene DLK Modulates Gene Expression in Human Myeloid Cells by Altering the Activity of Multiple Transcription Factors.. <i>Blood</i> , 2005, 106, 3428-3428.	0.6	0
481	Health-Risk Behaviors among Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2005, 106, 748-748.	0.6	0
482	Functional Comparison and Longitudinal Assessment of Tri-Functional T-Cells Recognizing CMV pp65 and IE-1 Polypeptides in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.. <i>Blood</i> , 2006, 108, 2936-2936.	0.6	0
483	High dose chemotherapy for breast cancer: Out with the old, in with the new?. <i>Women's Oncology Review</i> , 2007, 6, 105-107.	0.0	0
484	Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.. <i>Blood</i> , 2007, 110, 3021-3021.	0.6	0
485	Non-Myeloablative Conditioning Regimen (NMCR) for Allogeneic Bone Marrow Transplantation (BMT) in Patients with Severe Aplastic Anemia (SAA).. <i>Blood</i> , 2007, 110, 4943-4943.	0.6	0
486	Multicytokine and Polyfunctional CMV-Specific T Cells Are Associated with Stem Cell Transplant Donor CMV Serostatus.. <i>Blood</i> , 2007, 110, 4992-4992.	0.6	0

#	ARTICLE	IF	CITATIONS
487	Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥ 60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 1089-1089.	0.6	0
488	Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in "High Risk" B-Cell Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 3500-3500.	0.6	0
489	Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.. Blood, 2007, 110, 3030-3030.	0.6	0
490	Chronic Graft vs. Host Disease (cGVHD) Hinders Long-Term Functional Recovery after Hematopoietic Cell Transplantation.. Blood, 2007, 110, 634-634.	0.6	0
491	In Vivo Activated CD103+CD4+ Regulatory T Cells Ameliorate Ongoing Chronic GVHD.. Blood, 2007, 110, 350-350.	0.6	0
492	Analysis of 120 Pediatric Patients with Non-Malignant Disorders Transplanted Using Unrelated Plasma Depleted Cord Blood and the Role of Post-Thaw Wash. Blood, 2008, 112, 4406-4406.	0.6	0
493	Decline in Sexual Functioning Over a 3-Year Period after Hematopoietic Cell Transplantation (HCT): Gender-Specific Impact of Total Body Irradiation (TBI) and Chronic Graft-Versus-Host Disease (cGvHD). Blood, 2008, 112, 743-743.	0.6	0
494	Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs. Blood, 2008, 112, 3628-3628.	0.6	0
495	Longitudinal Trends in Peripheral Blood Parameters Predict Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/ AML) after Autologous Transplantation for Lymphoma.. Blood, 2008, 112, 2133-2133.	0.6	0
496	Truncation in CCND1 mRNA 3' UTR Is Associated with An Aggressive Phenotype and Chemoresistance. Blood, 2008, 112, 5287-5287.	0.6	0
497	Differential Morbidity by Ethnicity in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood, 2008, 112, 454-454.	0.6	0
498	Impact of Donor Serostatus on CMV Reactivation and Reconstitution of Multi-Function CMV-Specific T Cells in CMV-Positive Transplant Recipients. Blood, 2008, 112, 4339-4339.	0.6	0
499	Genomic Alterations in Hodgkin <sup>+</sup> and Reed/Sternberg (HRS) Cells at Disease Onset Reveals Distinct Signatures for Chemosensitive and Primary Refractory Hodgkin <sup>+</sup> Lymphoma.. Blood, 2008, 112, 1451-1451.	0.6	0
500	A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).. Blood, 2009, 114, 1225-1225.	0.6	0
501	Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.. Blood, 2009, 114, 3423-3423.	0.6	0
502	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL).. Blood, 2009, 114, 1192-1192.	0.6	0
503	Mechanisms of Susceptibility to 11q23 MLL Gene Locus Rearrangements in CD34+ Cells Exposed to Etoposide.. Blood, 2009, 114, 185-185.	0.6	0
504	A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma.. Blood, 2009, 114, 3403-3403.	0.6	0

#	ARTICLE	IF	CITATIONS
505	Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.. Blood, 2009, 114, 1682-1682.	0.6	0
506	Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels.. Blood, 2009, 114, 1690-1690.	0.6	0
507	Genetic Susceptibility to Therapy-Related Leukemia (t-MDS/AML) After Hodgkin Lymphoma (HL) or Non-Hodgkin Lymphoma (NHL).. Blood, 2009, 114, 199-199.	0.6	0
508	90.y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).. Blood, 2009, 114, 3357-3357.	0.6	0
509	Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period. Blood, 2010, 116, 933-933.	0.6	0
510	Dose Dependent Effect of Deferasirox on Hematopoietic Progenitors of Myelodysplastic Syndrome. Blood, 2010, 116, 3994-3994.	0.6	0
511	Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era. Blood, 2010, 116, 902-902.	0.6	0
512	Extramedullary Relapse Following Reduced Intensity AlloHCT for Adult AML.. Blood, 2010, 116, 3467-3467.	0.6	0
513	Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/AML) After Conventionally-Treated Breast Cancer: Impact of Cytogenetics on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2011, 118, 4149-4149.	0.6	0
514	Genetic Susceptibility to Therapy-Related Leukemia – Role of Expression Quantitative Trait Loci (eQTL). Blood, 2011, 118, 2438-2438.	0.6	0
515	Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study. Blood, 2011, 118, 2555-2555.	0.6	0
516	Nrf2 Deficiency Leads to Altered Hematopoietic Stem Cell Function and Increased Sensitivity to Alkylating Agent Induced Myeloid Dysplasia,. Blood, 2011, 118, 3828-3828.	0.6	0
517	Tissue Parenchymal Cell Expression of B7-H1 Inhibits Infiltrating T Cell Expansion and Prevents Persistence of Graft-Versus-Host Disease. Blood, 2011, 118, 2974-2974.	0.6	0
518	Eosinophilia As a Biomarker Predicting the Occurrence of Chronic Graft Versus Host Disease,. Blood, 2011, 118, 4084-4084.	0.6	0
519	Detection and Characterization of Antigen-Driven CD8+ T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma. Blood, 2011, 118, 953-953.	0.6	0
520	Human Papillomavirus (HPV)-Attributable Subsequent Neoplasms (SNs) After Hematopoietic Cell Transplantation (HCT) – a Potentially Preventable Outcome. Blood, 2012, 120, 605-605.	0.6	0
521	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. Blood, 2012, 120, 3698-3698.	0.6	0
522	Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades. Blood, 2012, 120, 606-606.	0.6	0

#	ARTICLE	IF	CITATIONS
523	Dasatinib Enhances Targeting of Human AML Leukemia Stem Cells by Chemotherapeutic Agents Via Activation of p53. <i>Blood</i> , 2012, 120, 3590-3590.	0.6	0
524	Nrf2 Deficiency Leads to Reduced Hematopoietic Stem Cell Self-Renewal and Increased Sensitivity to Genotoxic Stressors Through Impaired P53 Function. <i>Blood</i> , 2012, 120, 397-397.	0.6	0
525	Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia. <i>Blood</i> , 2012, 120, 218-218.	0.6	0
526	Quantitative Monitoring Of Wilmsâ€™ Tumor 1 Expression In Predicting Relapse After Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Acute Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2013, 122, 2075-2075.	0.6	0
527	Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 1808-1808.	0.6	0
528	Increased Risk Of Brain Tumors Among First-Degree Relatives Of Patients With Therapy-Related Myelodysplasia and Acute Myeloid Leukemia (t-MDS/AML). <i>Blood</i> , 2013, 122, 5228-5228.	0.6	0
529	Selective Anti Leukemic Activity Of Low Dose Decitabine In Combination With Ruxolitinib Against Stem/Progenitor Cells From Elderly AML Patients. <i>Blood</i> , 2013, 122, 2690-2690.	0.6	0
530	Development Of t-MDS In Patients Undergoing Autologous Transplantation For Lymphoma Is Not Associated With Increased Frequency Of Mitochondrial DNA Mutations. <i>Blood</i> , 2013, 122, 1535-1535.	0.6	0
531	Long-Term Health-Related Outcomes In Survivors Of Childhood Hematopoietic Cell Transplantation (HCT): A Report From The Bone Marrow Transplant Survivor Study (BMTSS). <i>Blood</i> , 2013, 122, 553-553.	0.6	0
532	Randomized Trial of a Novel CMV Vaccine (CMVPepVax) after Allogeneic HCT: Elevated CMV-Specific Immune Response, Reduction in Chronic GvHD and CMV Reactivation Only in Vaccine Arm Patients. <i>Blood</i> , 2014, 124, 183-183.	0.6	0
533	Feasibility of administering a geriatric assessment to older adults with cancer using web-based and touchscreen platforms.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9536-9536.	0.8	0
534	Differences between patient and caregiver assessments and their association with caregiver burden in caregivers of older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9545-9545.	0.8	0
535	Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies. <i>Blood</i> , 2015, 126, 2731-2731.	0.6	0
536	Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1961-1961.	0.6	0
537	Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy. <i>Blood</i> , 2015, 126, 3086-3086.	0.6	0
538	Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?. <i>Blood</i> , 2015, 126, 3179-3179.	0.6	0
539	Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation. <i>Blood</i> , 2015, 126, 1875-1875.	0.6	0
540	New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. <i>Blood</i> , 2016, 128, 2161-2161.	0.6	0

#	ARTICLE	IF	CITATIONS
541	Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. <i>Blood</i> , 2016, 128, 4651-4651.	0.6	0
542	MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 1752-1752.	0.6	0
543	Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. <i>Blood</i> , 2018, 132, 1411-1411.	0.6	0
544	Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 1549-1549.	0.6	0
545	Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , 2018, 132, 3386-3386.	0.6	0
546	Venous Thromboembolism in Blood or Marrow Transplant (BMT) Survivors: A Report from BMT Survivor Study (BMTSS). <i>Blood</i> , 2018, 132, 823-823.	0.6	0
547	Targeted Delivery of CpG-Mir-146a Mimic Oligonucleotides As a Therapeutic Strategy to Reduce NF- $\kappa$ B-Mediated Pathogenic Inflammation and Myeloid Leukemia Progression. <i>Blood</i> , 2018, 132, 3501-3501.	0.6	0
548	Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study. <i>Blood</i> , 2018, 132, 2007-2007.	0.6	0
549	Burden of Morbidity Borne By Survivors of Multiple Myeloma (MM) Treated with Autologous Blood or Marrow Transplant (BMT) – Results of the BMT Survivor Study (BMTSS). <i>Blood</i> , 2018, 132, 2127-2127.	0.6	0
550	DNA Repair Genes May Influence Cognitive Outcomes in Adult Patients with Hematologic Malignancies (HM) Treated with Blood or Marrow Transplantation (BMT). <i>Blood</i> , 2018, 132, 3411-3411.	0.6	0
551	Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 620-620.	0.6	0
552	Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation. <i>Blood</i> , 2018, 132, 2181-2181.	0.6	0
553	CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies. <i>Blood</i> , 2018, 132, 776-776.	0.6	0
554	YIA19-005: Immunotherapy for Prostate Cancer Combining CAR-Engineered T Cells with Targeted Immune Checkpoint Inhibition. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, YIA19-005.	2.3	0
555	Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors. <i>Blood</i> , 2019, 134, 2011-2011.	0.6	0
556	Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. <i>Blood</i> , 2021, 138, 3037-3037.	0.6	0
557	Subsequent Malignant Neoplasms of the Gastrointestinal Tract after Blood or Marrow Transplantation - a BMTSS Report. <i>Blood</i> , 2021, 138, 3923-3923.	0.6	0
558	Trends in Late Mortality and Life Expectancy after Autologous Blood or Marrow Transplantation (BMT) Performed over Three Decades - a BMT Survivor Study (BMTSS) Report. <i>Blood</i> , 2021, 138, 484-484.	0.6	0

#	ARTICLE	IF	CITATIONS
559	CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 2783-2783.	0.6	0
560	Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association. <i>Blood</i> , 2021, 138, 3887-3887.	0.6	0
561	Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq. <i>Blood</i> , 2021, 138, 1808-1808.	0.6	0
562	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. <i>Blood</i> , 2021, 138, 3955-3955.	0.6	0
563	A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant. <i>Blood</i> , 2021, 138, 2887-2887.	0.6	0
564	The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type. <i>Blood</i> , 2021, 138, 1776-1776.	0.6	0
565	Conditioning Intensity and Probability of Live Birth after Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). <i>Blood</i> , 2021, 138, 2905-2905.	0.6	0
566	CTIM-29. CLINICAL EVALUATION OF CHLOROTOXIN-DIRECTED CAR T CELLS FOR PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi57-vi57.	0.6	0
567	Single-Cell Analysis By Mass Cytometry Reveals CD19 CAR T Cell Spatiotemporal Plasticity in Patients. <i>Blood</i> , 2021, 138, 2794-2794.	0.6	0
568	Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
569	Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
570	Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program. <i>Blood</i> , 2020, 136, 10-10.	0.6	0
571	Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2020, 136, 10-11.	0.6	0
572	Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
573	Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization. <i>Blood</i> , 2020, 136, 16-17.	0.6	0
574	Genome-wide variants and polygenic risk scores for cognitive impairment following blood or marrow transplantation. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
575	Methods for Gene Transfer: Genetic Manipulation of Hematopoietic Stem Cells. , 0, , 107-117.		0
576	AIDS and Hematopoietic Transplantation: HIV Infection, AIDS, Lymphoma and Gene Therapy. , 0, , 1369-1384.		0

#	ARTICLE	IF	CITATIONS
577	Hematopoietic Cell Transplantation for Sickle Cell Disease. , 0 , 1417-1429.		0
578	Hematopoietic Cell Transplantation for Osteopetrosis. , 0 , 1443-1454.		0
579	Hematopoietic Cell Transplantation for Macrophage and Granulocyte Disorders. , 0 , 1471-1482.		0
580	Hematopoietic Cell Transplantation in the 21st Century. , 0 , 1505-1510.		0
581	Pharmacologic Basis for High-Dose Chemotherapy. , 0 , 130-157.		0
582	Pharmacology and the Use of Immunosuppressive Agents After Hematopoietic Cell Transplantation. , 0 , 209-220.		0
583	Molecular Inhibition of Gene Expression in Hematopoietic Cells. , 0 , 258-271.		0
584	The Detection and Significance of Minimal Residual Disease. , 0 , 272-285.		0
585	Pathology of Hematopoietic Cell Transplantation. , 0 , 286-299.		0
586	The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation. , 0 , 447-462.		0
587	Nursing Issues in Hematopoietic Cell Transplantation. , 0 , 469-482.		0
588	The Patient's Perspective. , 0 , 483-487.		0
589	Ethical Issues in Hematopoietic Cell Transplantation. , 0 , 488-496.		0
590	Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients. , 0 , 507-518.		0
591	Histocompatibility. , 0 , 31-42.		0
592	Sexuality After Hematopoietic Cell Transplantation. , 0 , 519-528.		0
593	Hematopoietic Cell Procurement, Processing and Transplantation: Regulation and Accreditation. , 0 , 529-537.		0
594	Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation. , 0 , 588-598.		0

#	ARTICLE	IF	CITATIONS
595	Cryopreservation of Hematopoietic Cells. , 0 , 599-612.		0
596	Recombinant Growth Factors After Hematopoietic Cell Transplantation. , 0 , 613-623.		0
597	Functional Evolution of the Major Histocompatibility Complex. , 0 , 43-52.		0
598	Neurological Complications of Hematopoietic Cell Transplantation. , 0 , 811-823.		0
599	The Hematopoietic Microenvironment. , 0 , 53-61.		0
600	Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation. , 0 , 833-852.		0
601	Vaccination of Hematopoietic Cell Transplant Recipients. , 0 , 862-872.		0
602	Molecular Aspects of Stem Cell Renewal. , 0 , 62-68.		0
603	Allogeneic Transplantation for Paroxysmal Nocturnal Hemoglobinuria. , 0 , 1002-1006.		0
604	Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia. , 0 , 1018-1024.		0
605	Allogeneic Transplantation for Acute Myeloid Leukemia in Children. , 0 , 1040-1054.		0
606	Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma. , 0 , 1096-1104.		0
607	Management of Relapse After Allogeneic Transplantation. , 0 , 1150-1163.		0
608	Autologous and Allogeneic Hematopoietic Cell Transplantation for Hodgkin's Disease. , 0 , 1189-1206.		0
609	Expansion of Hematopoietic Stem Cells. , 0 , 96-106.		0
610	Autologous Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. , 0 , 1238-1249.		0
611	Autologous Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia. , 0 , 1250-1261.		0
612	Autologous Hematopoietic Cell Transplantation for AL Amyloidosis. , 0 , 1283-1297.		0

#	ARTICLE	IF	CITATIONS
613	Hematopoietic Cell Transplantation in Germ Cell Tumors. , 0 , 1308-1319.		0
614	Hematopoietic Cell Transplantation in Ovarian Carcinoma. , 0 , 1320-1332.		0
615	Hematopoietic Cell Transplantation for Brain Tumors. , 0 , 1345-1353.		0
616	Genetic Manipulation of Hematopoietic Stem Cells. , 0 , 116-128.		0
617	Critical Care of the Hematopoietic Cell Transplant Recipient. , 0 , 1539-1550.		0
618	Secondary Malignancies after Hematopoietic Cell Transplantation. , 0 , 1638-1652.		0
619	Hematopoietic Cell Transplantation in the Future. , 0 , 1671-1676.		0
620	Overview of Hematopoietic Cell Transplantation Immunology. , 0 , 129-144.		0
621	Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation. , 0 , 163-175.		0
622	Radioimmunotherapy and Hematopoietic Cell Transplantation. , 0 , 351-364.		0
623	The Detection and Significance of Minimal Residual Disease. , 0 , 376-389.		0
624	Biostatistical Methods in Hematopoietic Cell Transplantation. , 0 , 406-427.		0
625	Ethical Issues in Hematopoietic Cell Transplantation. , 0 , 478-487.		0
626	Sexuality Following Hematopoietic Cell Transplantation: An Important Health-related Quality of Life Issue. , 0 , 515-525.		0
627	Hematopoietic Cell Transplantation: The Patient's Perspective. , 0 , 526-532.		0
628	Hematopoietic Cell Procurement, Processing, and Transplantation: Standards, Accreditation, and Regulation. , 0 , 533-543.		0
629	Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Embryonic Stem Cells. , 0 , 23-35.		0
630	Removal of Tumor Cells from the Hematopoietic Graft. , 0 , 605-617.		0

#	ARTICLE	IF	CITATIONS
631	Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation. , 0, , 618-630.		0
632	Cryopreservation of Hematopoietic Cells. , 0, , 631-644.		0
633	Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation. , 0, , 645-656.		0
634	Donor Selection for Hematopoietic Cell Transplantation. , 0, , 692-703.		0
635	Hematopoietic Cell Transplantation for Aplastic Anemia. , 0, , 705-726.		0
636	Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria. , 0, , 727-733.		0
637	Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia. , 0, , 751-760.		0
638	Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia. , 0, , 775-790.		0
639	Hematopoietic Cell Transplantation for Hodgkin's Disease. , 0, , 860-877.		0
640	Non-Hodgkin's Lymphoma. , 0, , 878-896.		0
641	Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis. , 0, , 914-930.		0
642	Hematopoietic Cell Transplantation for Breast Cancer. , 0, , 931-947.		0
643	Hematopoietic Cell Transplantation in Germ Cell Tumors. , 0, , 948-957.		0
644	Hematopoietic Cell Transplantation for Renal Cell and other Solid Tumors. , 0, , 958-959.		0
645	Hematopoietic Cell Transplantation for Neuroblastoma. , 0, , 970-984.		0
646	Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors. , 0, , 985-1000.		0
647	Hematopoietic Cell Transplantation for Patients with Human Immunodeficiency Virus Infection. , 0, , 1001-1013.		0
648	Hematopoietic Cell Transplantation for Rare Hematologic Malignancies. , 0, , 1030-1042.		0

#	ARTICLE	IF	CITATIONS
649	Management of Relapse after Hematopoietic Cell Transplantation. , 0, , 1059-1075.		0
650	Hematopoietic Cell Transplantation for Thalassemia. , 0, , 1077-1089.		0
651	Hematopoietic Cell Transplantation for Sickle Cell Disease. , 0, , 1090-1104.		0
652	Hematopoietic Cell Transplantation for Macrophage and Granulocyte Disorders. , 0, , 1163-1177.		0
653	Hematopoietic Cell Transplantation for Fanconi's Anemia. , 0, , 1178-1199.		0
654	Mechanisms and Treatment of Graft Failure. , 0, , 1201-1218.		0
655	Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation. , 0, , 1219-1225.		0
656	T-Cell Depletion to Prevent Graft-versus-Host Disease. , 0, , 1275-1286.		0
657	Epstein-Barr Virus Infection. , 0, , 1410-1418.		0
658	Endocrine Complications Following Hematopoietic Cell Transplantation. , 0, , 1487-1522.		0
659	Common Potential Drug Interactions Following Hematopoietic Cell Transplantation. , 0, , 1523-1538.		0